WBMT Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy.

Archive ouverte

Alseraihy, A. | Mcgrath, E. | Niederwieser, D. | Chabannon, Christian | Szer, J. | Mohty, Mohamad | Kharfan-Dabaja, M. A. | Orchard, K. | Schwartz, J. | Rasheed, W. | Koh, M. | Kröger, N. | Kodera, Y. | Fakih, R. E. | Worel, N. | Manson, L. | Rintala, T. | Tabakhi, A. | Savani, B. | Gergis, U. | Sureda, A. | Eldridge, P. W. | Yakoub-Agha, Ibrahim | Hamadani, M. | Weisdorf, D. | Greinix, H. | Aljurf, M.

Edité par CCSD ; Elsevier -

International audience. Hematopoietic stem cell transplantation (HSCT) represents an example of a highly complex and costly medical procedure with major applications in hematology and oncology. It is associated with life-threatening complications and, consequently, increased demands on healthcare resources. Although improving quality is an integral component of healthcare strategic planning, drivers of quality may be variable, and there is logical debate as to what drives quality in HSCT. Moreover, HSCT programs differ in structure and availability of resources, which drive the type of transplantations provided and determine what is affordable and/or economically feasible. The complexity of HSCT procedures with involvement of different stakeholders necessitates not only regulatory frameworks, but also robust quality systems to ensure consistent standards, demonstrate transparency for regulators, and define what quality means within the HSCT program. In an era of escalating healthcare complexity and heightened fiscal responsibility, transparency and accountability, accreditation contributes to ensuring that care meets the highest standards and can serve as a risk mitigation strategy. Quality management has become an indispensable tool for the management of a complex medical intervention such as HSCT. It allows the transplantation team to monitor its activities and identify areas for continuous improvement. The Worldwide Network for Blood and Marrow Transplantation invited a group of international experts in HSCT and quality management to work on providing a summary document about the key elements in quality and accreditation in HSCT and highlight the foremost challenges of implementing them, with a special focus on low- and middle-income economies.

Consulter en ligne

Suggestions

Du même auteur

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

Archive ouverte | Snowden, J. A. | CCSD

International audience. For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. Th...

Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey.

Archive ouverte | Passweg, J. R. | CCSD

International audience. In 2020, 45,364 HCT in 41,016 patients, 18,796 (41%) allogeneic and 26,568 (59%) autologous in 690 centers were reported. Changes observed were as follows: total number of HCT −6.5%, allogene...

Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study.

Archive ouverte | Rius-Sansalvador, B. | CCSD

International audience. Allogeneic haematopoietic cell transplantation (alloHCT) has curative potential counterbalanced by its toxicity. Prognostic scores fail to include current era patients and alternative donors....

Chargement des enrichissements...